Vitals Knowledge Vault

GLP-1 Body Composition

4 min read

GLP-1 Body Composition

TL;DR

GLP-1 receptor agonists cause 21–45% of total weight lost to come from lean mass — a proportion comparable to non-pharmacologic caloric restriction at similar deficits. This is a caloric deficit effect, not a unique GLP-1 toxicity, but the absolute impact is larger in older adults, CKD patients, and sedentary individuals. The only evidence-supported preservation strategies are resistance training ≥3×/week and protein intake of 2.0–2.5 g/kg/day. No pharmacologic agent except bimagrumab has human lean-gain evidence, and bimagrumab’s obesity Phase 3 path is uncertain.

Lean Mass Fraction of Weight Lost

SourceLean Mass as % of Total Weight LostEvidence Grade
GLP-1 RA systematic review21–40%Confirmed (PMID:40289060)
STEP 1 DEXA subset (semaglutide 2.4 mg, 68 wk)~45% (6.92 kg LST / 15.3 kg total)Supported (PMCID:PMC8089287)
Network meta-analysis (Coutinho et al.)~25%Supported
Retatrutide Phase 2”Largely preserved” but lean fraction up to ~40% class range expectedSupported (Lancet Diabetol 2025)

The commonly cited 25–35% range understates what some trials show (STEP 1: ~45%). The actual fraction depends on:

  • Protein intake during therapy
  • Concurrent resistance training
  • Dose and duration
  • Patient population (older = higher fraction)

Important framing

The lean mass loss is proportional to the caloric deficit — it is not a unique GLP-1 toxicity. Non-pharmacologic caloric restriction at comparable deficits produces a similar lean fraction. The concern is that GLP-1-induced deficits are large and sustained, making the absolute lean mass impact clinically significant.

See GLP-1 Muscle Preservation for the full preservation evidence review.

Safety Signals

FindingSeveritySource
GLP-1 causes 21–40% of weight lost as lean mass; greatest loss in first 3–6 monthsIntermediatePMID:40289060
Semaglutide accelerates sarcopenia in older adults with T2D over 24 months (grip decline + gait reduction)SeverePMID:40631351
GLP-1 RA: +11% fragility fracture risk in adults ≥65 vs. other diabetes medsSeverePMID:41665888
Semaglutide reduces hip BMD 2.6%, lumbar spine BMD 2.1% within 1 yearIntermediatePMID:41655226
>20% develop nutritional deficiencies within 1 year; vitamin D deficiency most common (13.6%)IntermediatePMID:40584822
Glucagon suppression may drive muscle proteolysis via impaired hepatic amino acid clearance (mechanistic hypothesis)IntermediatePMID:41311515

High-Risk Populations

PopulationRisk factor
Older adults (≥65)Highest absolute risk; semaglutide specifically accelerates functional decline in this group
CKD patientsUremic myopathy, chronic inflammation, metabolic acidosis, vitamin D deficiency — all independently drive muscle wasting; CKD excluded from GLP-1 registration trials
Sedentary individualsNo exercise-mediated muscle protein synthesis counterbalance
Inadequate protein intake (<1.2 g/kg/day)Cannot support muscle protein synthesis during caloric deficit
Retatrutide usersGCGR activation adds catabolic signal on top of GLP-1/GIP effects; lean mass fraction may be higher than dual agonists

Alarm Thresholds

ContextThresholdBasis
Lean mass loss during GLP-1 therapy (general)>25% of total weight lost as lean massLower end of 21–45% range
BIA-measured ALM loss>5% in 30 daysExtrapolated from catabolism literature; not GLP-1-specific validated
Grip strength decline>10% from personal baseline in 30 daysClinical minimal detectable change
Gait speed decline≥0.1 m/s from baselineIndependently associated with adverse outcomes (PMC6302764)
Protein intake<1.2 g/kg/day during GLP-1 therapyBelow threshold for muscle protein synthesis

Preservation Evidence

InterventionEffect on Lean FractionEvidence
Resistance training ≥3×/weekReduces lean fraction (best available evidence)Meta-analysis
Protein 2.0–2.5 g/kg/daySupports MPS during deficit; necessary but not sufficient aloneGeneral catabolism literature
Bimagrumab (ActRII blockade)+3.6% lean mass at 48 weeks (Phase 2); clinical path uncertainPhase 2 evidence
GHK-Cu, BPC-157, TB-500Zero published human RCTs for muscle-specific anabolic effectsGap
Omega-3 supplementationNo effect on muscle protein synthesis during caloric restriction (SMD 0.03)Meta-analysis — null
BCAA supplementationIdentical lean mass loss vs. control during caloric restrictionRCT — null

See GLP-1 Muscle Preservation for the full evidence table.

Vitals Coaching Implications

Practical detection logic

  1. BIA monthly trend — flag if >5% ALM loss in 30 days during GLP-1 therapy
  2. Grip strength monthly — flag if >10% decline from 90-day personal baseline
  3. Gait speed continuous — flag if ≥0.1 m/s decline from 90-day rolling average
  4. Protein intake check — flag if <1.4 g/kg/day; urgent review if <1.2 g/kg/day
  5. DXA referral — baseline before/early in GLP-1 therapy; then per Tier 3 triggers or annually for high-risk

What to tell users on GLP-1 therapy

  • Scale weight alone is misleading without body composition context
  • Resistance training is the anchor intervention — it is not optional if preserving muscle is a goal
  • Protein intake must be intentionally prioritized during a caloric deficit; appetite suppression makes this non-intuitive
  • Consumer BIA devices are not accurate enough for individual tracking decisions

Key PMIDs

PMIDTopic
40289060GLP-1 systematic review: 21–40% lean mass fraction
PMC8089287STEP 1 DEXA: ~45% lean mass fraction
40631351Semaglutide accelerates sarcopenia in T2D elderly
41665888GLP-1 fracture risk +11% in ≥65
41655226Semaglutide BMD reduction 2.6% hip, 2.1% lumbar spine
40584822GLP-1 nutritional deficiencies 22% at 1 year
41311515Glucagon suppression and muscle proteolysis hypothesis

Graph View

Backlinks